241 related articles for article (PubMed ID: 16511518)
1. Fragile sites are preferential targets for integrations of MLV vectors in gene therapy.
Bester AC; Schwartz M; Schmidt M; Garrigue A; Hacein-Bey-Abina S; Cavazzana-Calvo M; Ben-Porat N; Von Kalle C; Fischer A; Kerem B
Gene Ther; 2006 Jul; 13(13):1057-9. PubMed ID: 16511518
[TBL] [Abstract][Full Text] [Related]
2. Looking into the safety of AAV vectors.
Kay MA; Nakai H
Nature; 2003 Jul; 424(6946):251. PubMed ID: 12867952
[No Abstract] [Full Text] [Related]
3. Murine leukemia virus vector integration favors promoter regions and regional hot spots in a human T-cell line.
Tsukahara T; Agawa H; Matsumoto S; Matsuda M; Ueno S; Yamashita Y; Yamada K; Tanaka N; Kojima K; Takeshita T
Biochem Biophys Res Commun; 2006 Jul; 345(3):1099-107. PubMed ID: 16713998
[TBL] [Abstract][Full Text] [Related]
4. Clinical research. Gene therapy a suspect in leukemia-like disease.
Marshall E
Science; 2002 Oct; 298(5591):34-5. PubMed ID: 12364755
[No Abstract] [Full Text] [Related]
5. Transcription start regions in the human genome are favored targets for MLV integration.
Wu X; Li Y; Crise B; Burgess SM
Science; 2003 Jun; 300(5626):1749-51. PubMed ID: 12805549
[TBL] [Abstract][Full Text] [Related]
6. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.
Hacein-Bey-Abina S; Von Kalle C; Schmidt M; McCormack MP; Wulffraat N; Leboulch P; Lim A; Osborne CS; Pawliuk R; Morillon E; Sorensen R; Forster A; Fraser P; Cohen JI; de Saint Basile G; Alexander I; Wintergerst U; Frebourg T; Aurias A; Stoppa-Lyonnet D; Romana S; Radford-Weiss I; Gross F; Valensi F; Delabesse E; Macintyre E; Sigaux F; Soulier J; Leiva LE; Wissler M; Prinz C; Rabbitts TH; Le Deist F; Fischer A; Cavazzana-Calvo M
Science; 2003 Oct; 302(5644):415-9. PubMed ID: 14564000
[TBL] [Abstract][Full Text] [Related]
7. Is it going to be SIN?: a European Society of Gene Therapy commentary. Phasing-out the clinical use of non self-inactivating murine leukemia virus vectors: initiative on hold.
Buchholz CJ; Cichutek K
J Gene Med; 2006 Oct; 8(10):1274-6. PubMed ID: 17001625
[TBL] [Abstract][Full Text] [Related]
8. [Differences in the MLV and HIV-1 integration sites could be important for gene therapy].
Jeanteur P
Bull Cancer; 2003; 90(8-9):671. PubMed ID: 14626239
[No Abstract] [Full Text] [Related]
9. Lessons learned from gene therapy concerning and the use of integrating vectors and the possible risk of insertional oncogenesis.
Cichutek K
Dev Biol (Basel); 2006; 123():29-34; discussion 55-73. PubMed ID: 16566434
[No Abstract] [Full Text] [Related]
10. A tragic setback.
Check E
Nature; 2002 Nov; 420(6912):116-8. PubMed ID: 12432357
[No Abstract] [Full Text] [Related]
11. Gene therapy resumes.
Novak K
Nat Rev Cancer; 2002 Nov; 2(11):813. PubMed ID: 12442759
[No Abstract] [Full Text] [Related]
12. Genetic modification of hematopoietic cells using retroviral and lentiviral vectors: safety considerations for vector design and delivery into target cells.
Dropulic B
Curr Hematol Rep; 2005 Jul; 4(4):300-4. PubMed ID: 16009045
[TBL] [Abstract][Full Text] [Related]
13. Genotoxicity of retroviral integration in hematopoietic cells.
Nienhuis AW; Dunbar CE; Sorrentino BP
Mol Ther; 2006 Jun; 13(6):1031-49. PubMed ID: 16624621
[TBL] [Abstract][Full Text] [Related]
14. Insertion of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns.
Laufs S; Nagy KZ; Giordano FA; Hotz-Wagenblatt A; Zeller WJ; Fruehauf S
Mol Ther; 2004 Nov; 10(5):874-81. PubMed ID: 15509505
[TBL] [Abstract][Full Text] [Related]
15. The leukemogenic risk of integrating retroviral vectors in hematopoietic stem cell gene therapy applications.
Kang EM; Tisdale JF
Curr Hematol Rep; 2004 Jul; 3(4):274-81. PubMed ID: 15217557
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy insertional mutagenesis insights.
Davé UP; Jenkins NA; Copeland NG
Science; 2004 Jan; 303(5656):333. PubMed ID: 14726584
[No Abstract] [Full Text] [Related]
17. Harmful potential of viral vectors fuels doubts over gene therapy.
Check E
Nature; 2003 Jun; 423(6940):573-4. PubMed ID: 12789298
[No Abstract] [Full Text] [Related]
18. Infection with retroviral vectors leads to perturbed DNA replication increasing vector integrations into fragile sites.
Bester AC; Kafri M; Maoz K; Kerem B
Sci Rep; 2013; 3():2189. PubMed ID: 23852038
[TBL] [Abstract][Full Text] [Related]
19. Occurrence of leukaemia following gene therapy of X-linked SCID.
Kohn DB; Sadelain M; Glorioso JC
Nat Rev Cancer; 2003 Jul; 3(7):477-88. PubMed ID: 12835668
[TBL] [Abstract][Full Text] [Related]
20. Retroviral vector insertions in T-lymphocytes used for suicide gene therapy occur in gene groups with specific molecular functions.
Giordano FA; Fehse B; Hotz-Wagenblatt A; Jonnakuty S; del Val C; Appelt JU; Nagy KZ; Kuehlcke K; Naundorf S; Zander AR; Zeller WJ; Ho AD; Fruehauf S; Laufs S
Bone Marrow Transplant; 2006 Aug; 38(3):229-35. PubMed ID: 16785865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
